<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20230929059548N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-10-24</date_registration>
      <primary_sponsor>Shiraz University of Medical Sciences</primary_sponsor>
      <public_title>Investigation the effect of mentalization - based treatment on the impulsive behaviors in cancer patients</public_title>
      <acronym></acronym>
      <scientific_title>Investigating the effect of mentalization-based treatment on impulsive behaviors in cancer patients undergoing treatment</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-10-23</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>54</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/73080</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Education/Guidance, Randomization description: The samples will be allocated to two control and intervention groups by randomization method of permutation blocks. Finally, the sample size was considered to be 54, and for proportionality and equality of allocation, the samples will be placed in 9 blocks of 6. The random allocation list will be prepared by Random Allocation software. Randomization will be done individually.
Concealment will also be one-way blind. In this way, the people who analyze the results and the people who take the pre-test and post-test from the participants are unaware of the intervention, Blinding description: Blinding is performed in such a way that the people who analyze the results (outcome evaluator) and the people who take the pre-test and post-test from the participants are unaware of the intervention.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Cancer patients.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Mentalization-based therapy (MBT) is a special type of psychodynamic psychotherapy invented by Bateman and Fonagy. MBT is based on two main concepts: Balbi's attachment theory and mentalization. The main focus of MBT is to help the client bring their subjective experiences to the level of consciousness and facilitate a coherent and full sense of psychological agency. The goal of treatment is to grow and strengthen the mentalizing capacity through therapeutic relationships and increase the capacity of the patient to recognize the thoughts and feelings he experiences. Batman and Fonagy treatment protocol includes two parts: preliminary MBT and individual and group MBT. Preliminary MBT consists of 12 group therapy sessions, which are held weekly and each session lasts 1.5 hours, and after these sessions, individual and group sessions are offered to people, which are held in a period of 18 months. But according to Batman and Fonagy's conclusion; Evidence that this arrangement is optimal is lacking, suggesting that MBT should now be offered for shorter durations as well as as group or individual therapy. Therefore, in this study, only 12 preliminary MBT sessions will be conducted in person for the intervention group. After completing the interventions, the questionnaires will be given to both groups again. In each session, according to the protocol, they are taught about topics that include; The first session (what is mentalization and a mentalizing stance?), the second session (what does it mean to have a problem with mentalizing?), the third session (why do we have emotions and what are the basic types?), the fourth session (mentalizing emotions), the fifth session (the significance of attachment relationships), the sixth session (attachment and mentalizing), the seventh session (what is meant by impulsive behavior?), the eighth and ninth sessions(mentalization-based treatment), the tenth session (anxiety, attachment and mentalizing), the session It is the eleventh (depression, attachment and mentalizing) and the twelfth session (summary and conclusion). In each meeting, the objectives of the same meeting along with assignments are presented to the participants. Intervention 2: Control group: The control group will receive the educational content after the end of the intervention.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no further information.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Hanieh Edalati</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Salman Farsi Blvd., Javanmardi Street, Eram Residential Complex, Block 2/6, Unit 131</address>
        <city>Shiraz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7145834538</zip>
        <telephone>+98 71 3730 7889</telephone>
        <email>hanie.edd@gmail.com</email>
        <affiliation>Shiraz University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Ladan Zarshenas</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Namazi Square, Fatemeh(P.B.U.H) School of Nursing and Midwifery</address>
        <city>Shiraz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7193613119</zip>
        <telephone>+98 71 3647 4254</telephone>
        <email>zarshenas@sums.ac.ir</email>
        <affiliation>Shiraz University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients with gastrointestinal cancer
Patients admitted to the outpatient department of Amir Shiraz Oncology Hospital
Willingness to participate in the study
Moderate to high impulsive behavior based on the Barrett Impulsivity Scale
Failure to participate in similar treatment sessions</inclusion_criteria>
      <agemin>no limit</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Suffering from chronic mental and cognitive diseases</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>Malignant</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Malignant neoplasms</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Other</i_code>
      <i_code>Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Mentalization-based therapy (MBT) is a special type of psychodynamic psychotherapy invented by Bateman and Fonagy. MBT is based on two main concepts: Balbi's attachment theory and mentalization. The main focus of MBT is to help the client bring their subjective experiences to the level of consciousness and facilitate a coherent and full sense of psychological agency. The goal of treatment is to grow and strengthen the mentalizing capacity through therapeutic relationships and increase the capacity of the patient to recognize the thoughts and feelings he experiences. Batman and Fonagy treatment protocol includes two parts: preliminary MBT and individual and group MBT. Preliminary MBT consists of 12 group therapy sessions, which are held weekly and each session lasts 1.5 hours, and after these sessions, individual and group sessions are offered to people, which are held in a period of 18 months. But according to Batman and Fonagy's conclusion; Evidence that this arrangement is optimal is lacking, suggesting that MBT should now be offered for shorter durations as well as as group or individual therapy. Therefore, in this study, only 12 preliminary MBT sessions will be conducted in person for the intervention group. After completing the interventions, the questionnaires will be given to both groups again. In each session, according to the protocol, they are taught about topics that include; The first session (what is mentalization and a mentalizing stance?), the second session (what does it mean to have a problem with mentalizing?), the third session (why do we have emotions and what are the basic types?), the fourth session (mentalizing emotions), the fifth session (the significance of attachment relationships), the sixth session (attachment and mentalizing), the seventh session (what is meant by impulsive behavior?), the eighth and ninth sessions(mentalization-based treatment), the tenth session (anxiety, attachment and mentalizing), the session It is the eleventh (depression, attachment and mentalizing) and the twelfth session (summary and conclusion). In each meeting, the objectives of the same meeting along with assignments are presented to the participants.</i_keyword>
      <i_keyword>Control group: The control group will receive the educational content after the end of the intervention.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Score of impulsive behaviors in cancer patients based on Barrett's impulsivity scale. Timepoint: Measuring the level of impulsive behaviors at the beginning and end of the study. Method of measurement: Barrett impulsivity questionnaire.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Shiraz University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-08-26</approval_date>
        <contact_name>Ethics Committee of Shiraz University of Medical Sciences</contact_name>
        <contact_address>Salman Farsi Blvd., Javanmardi Street, Eram Residential Complex, Block 2/6, Unit 131 Shiraz Fars Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
